PhRMA Firms Will Disclose “Ghost Writers,” Give Credit For Journal Work
Executive Summary
Manuscript writers and statisticians provided by drug sponsors to help present results from a clinical trial will be "recognized appropriately" as contributors to publications of the data, according to a draft policy paper on the ethics of clinical trials under development by the Pharmaceutical Research & Manufacturers of America
You may also be interested in...
FDA Clinical Trial Oversight: Agency Must Ensure “System Is Not Broken”
FDA needs to demonstrate to the public that the "clinical trial system is not broken," Associate Commissioner Murray Lumpkin, MD, told the American Association of Pharmaceutical Scientists' annual meeting in Toronto Nov. 11
Quintiles Rejects Buy-Out Offer From Founder Gillings, Weighs Options
Quintiles will look for potential buyers after rejecting an acquisition offer from founder and Chairman Dennis Gillings, PhD
FDA Clinical Trial Oversight: Agency Must Ensure “System Is Not Broken”
FDA needs to demonstrate to the public that the "clinical trial system is not broken," Associate Commissioner Murray Lumpkin, MD, told the American Association of Pharmaceutical Scientists' annual meeting in Toronto Nov. 11